Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition

References

• Steinman RM. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med 2007; 13:1155 - 9; http://dx.doi.org/10.1038/nm1643; PMID: 17917664
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; http://dx.doi.org/10.1016/j.semcancer.2012.01.011; PMID: 22313874
   PubMed Web of Science ®Google Scholar
• Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011; 3:77 - 96; http://dx.doi.org/10.2217/imt.10.95; PMID: 21174559
   PubMed Web of Science ®Google Scholar
• Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, et al. IL-6 is required for glioma development in a mouse model. Oncogene 2004; 23:3308 - 16; http://dx.doi.org/10.1038/sj.onc.1207455; PMID: 15064729
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474 - 88; http://dx.doi.org/10.1038/sj.onc.1203527; PMID: 10851046
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000 - 8; http://dx.doi.org/10.1038/sj.onc.1205260; PMID: 11960372
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41 - 51; http://dx.doi.org/10.1038/nri1995; PMID: 17186030
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175:4338 - 46; PMID: 16177074
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48 - 54; http://dx.doi.org/10.1038/nm976; PMID: 14702634
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323; PMID: 19244102
   PubMed Web of Science ®Google Scholar
• Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-07-1243; PMID: 17942891
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009; 1171:59 - 76; http://dx.doi.org/10.1111/j.1749-6632.2009.04911.x; PMID: 19723038
   PubMed Web of Science ®Google Scholar
• Xie J, Qian J, Yang J, Wang S, Freeman ME 3rd, Yi Q. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 2005; 33:564 - 72; http://dx.doi.org/10.1016/j.exphem.2005.03.001; PMID: 15850834
   PubMed Web of Science ®Google Scholar
• Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107:2432 - 9; http://dx.doi.org/10.1182/blood-2005-06-2486; PMID: 16291589
   PubMed Web of Science ®Google Scholar
• Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, et al. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients’ monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108:4071 - 7; http://dx.doi.org/10.1182/blood-2006-04-016980; PMID: 16917008
   PubMed Web of Science ®Google Scholar
• Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009; 15:4382 - 90; http://dx.doi.org/10.1158/1078-0432.CCR-09-0399; PMID: 19549770
   PubMed Web of Science ®Google Scholar
• Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168:4333 - 43; PMID: 11970975
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150 - 66; PMID: 9834220
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174; PMID: 17483367
   PubMed Web of Science ®Google Scholar
• Hegde S, Pahne J, Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004; 18:1439 - 41; PMID: 15247147
   PubMed Web of Science ®Google Scholar
• Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162:4567 - 75; PMID: 10201996
   PubMed Web of Science ®Google Scholar
• Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173:3844 - 54; PMID: 15356132
   PubMed Web of Science ®Google Scholar
• Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18:849 - 61; http://dx.doi.org/10.1016/S1074-7613(03)00152-3; PMID: 12818165
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007; 67:5479 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-06-3963; PMID: 17545630
   PubMed Web of Science ®Google Scholar
• van Cruijsen H, Oosterhoff D, Lindenberg JJ, Lougheed SM, Fehres C, Weijers K, et al. Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. Immunotherapy 2011; 3:1051 - 61; http://dx.doi.org/10.2217/imt.11.107; PMID: 21913828
   PubMed Web of Science ®Google Scholar
• Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007; 86:800 - 11; http://dx.doi.org/10.1177/154405910708600902; PMID: 17720847
   PubMed Web of Science ®Google Scholar
• Mögel I, Baumann S, Böhme A, Kohajda T, von Bergen M, Simon JC, et al. The aromatic volatile organic compounds toluene, benzene and styrene induce COX-2 and prostaglandins in human lung epithelial cells via oxidative stress and p38 MAPK activation. Toxicology 2011; 289:28 - 37; http://dx.doi.org/10.1016/j.tox.2011.07.006; PMID: 21801798
   PubMed Web of Science ®Google Scholar
• Yang WS, Park YC, Kim JH, Kim HR, Yu T, Byeon SE, et al. Nanostructured, self-assembling peptide K5 blocks TNF-α and PGE₂ production by suppression of the AP-1/p38 pathway. Mediators Inflamm 2012; Epub ahead of press http://dx.doi.org/10.1155/2012/489810; PMID: 22315508
   PubMed Web of Science ®Google Scholar
• Feng YJ, Li YY. The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. J Dig Dis 2011; 12:327 - 32; http://dx.doi.org/10.1111/j.1751-2980.2011.00525.x; PMID: 21955425
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011; 71:5467 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988; PMID: 21730023
   PubMed Web of Science ®Google Scholar
• Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109 - 21; http://dx.doi.org/10.1084/jem.20110399; PMID: 22213806
   PubMed Web of Science ®Google Scholar
• Xie J, Qian J, Wang S, Freeman ME 3rd, Epstein J, Yi Q. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol 2003; 171:4792 - 800; PMID: 14568957
   PubMed Web of Science ®Google Scholar
• Harizi H, Limem I, Gualde N. CD40 engagement on dendritic cells induces cyclooxygenase-2 and EP2 receptor via p38 and ERK MAPKs. Immunol Cell Biol 2011; 89:275 - 82; http://dx.doi.org/10.1038/icb.2010.94; PMID: 20697426
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang X, Darrah PA, Mosser DM. The regulation of Th1 responses by the p38 MAPK. J Immunol 2010; 185:6205 - 13; http://dx.doi.org/10.4049/jimmunol.1000243; PMID: 20937847
   PubMed Web of Science ®Google Scholar
• Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005; 5:929 - 39; http://dx.doi.org/10.2174/1568026054985911; PMID: 16178738
   PubMed Web of Science ®Google Scholar
• Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011; 17:5850 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-10-2574; PMID: 21673068
   PubMed Web of Science ®Google Scholar
• Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008; 111:3050 - 61; http://dx.doi.org/10.1182/blood-2007-11-122408; PMID: 18180378
   PubMed Web of Science ®Google Scholar
• Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004; 165:1853 - 63; http://dx.doi.org/10.1016/S0002-9440(10)63238-5; PMID: 15579430
   PubMed Web of Science ®Google Scholar
• Wu L, Du H, Li Y, Qu P, Yan C. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 2011; 179:2131 - 41; http://dx.doi.org/10.1016/j.ajpath.2011.06.028; PMID: 21864492
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao J, Liu K, Zhao J, Yang H, Huang Y, et al. MAPK/ERK1/2 signaling mediates endothelial-like differentiation of immature DCs in the microenvironment of esophageal squamous cell carcinoma. Cell Mol Life Sci 2010; 67:2091 - 106; http://dx.doi.org/10.1007/s00018-010-0316-8; PMID: 20221785
   PubMed Web of Science ®Google Scholar
• Adler HS, Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle 2008; 7:169 - 70; http://dx.doi.org/10.4161/cc.7.2.5312; PMID: 18212528
   PubMed Web of Science ®Google Scholar
• Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196:121 - 35; http://dx.doi.org/10.1016/0022-1759(96)00079-8; PMID: 8841451
   PubMed Web of Science ®Google Scholar
• van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, et al. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 2006; 176:5191 - 8; PMID: 16621983
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62:5736 - 42; PMID: 12384532
   PubMed Web of Science ®Google Scholar
• Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S, et al. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 2000; 11:965 - 70; http://dx.doi.org/10.1023/A:1008363601515; PMID: 11038032
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345 - 50; http://dx.doi.org/10.1016/S0140-6736(98)07186-4; PMID: 9950438
   PubMed Web of Science ®Google Scholar